Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The current trial will test the combination of darolutamide with SBRT, in oligometastatic
recurrent hormone sensitive prostate cancer. We hypothesize that the addition of short-term
darolutamide improves metastasis-free survival when added to SBRT without a detrimental
impact on the QoL. Considering the large reluctance of both patients and physicians to be
randomized to observation, we propose to use the historical data from previous reported
randomized trials (STOMP and ORIOLE) as a comparator to explore as a secondary endpoint.